Cancer Discovery · 2014 · 441 citations · 20 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCombination ImmunotherapyImmunotherapy For Solid TumorsT Cell Responses To TumorsTumor-infiltrating LymphocytesAntitumor Immune ActivationCancer-associated ImmunosuppressionImmunosuppressive MicroenvironmentInnate Antitumor ImmunityLymphocyte PhysiologyLymphocyte RecruitmentMyeloid-derived Suppressor Cell InfiltrationTumor Immunogenicity
Cancer immunotherapy holds promise yet is constrained by tumor strategies that impair antigen presentation, lymphocyte activation, and homing through soluble mediators, vascular alterations, and immunosuppressive cells. The study investigates tumor‑exploited immunosuppressive mechanisms and evaluates emerging therapies that target lymphocyte trafficking. The authors analyze these pathways and assess therapeutic approaches designed to enhance lymphocyte infiltration into solid tumors. Published in Cancer Discovery, vol.
Abstract Summary: Cancer immunotherapy has great promise, but is limited by diverse mechanisms used by tumors to prevent sustained antitumor immune responses. Tumors disrupt antigen presentation, T/NK–cell activation, and T/NK–cell homing through soluble and cell-surface mediators, the vasculature, and immunosuppressive cells such as myeloid-derived suppressor cells and regulatory T cells. However, many molecular mechanisms preventing the efficacy of antitumor immunity have been identified and can be disrupted by combination immunotherapy. Here, we examine immunosuppressive mechanisms exploited by tumors and provide insights into the therapies under development to overcome them, focusing on lymphocyte traffic. Cancer Discov; 4(5); 522–6. ©2014 AACR.
20
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Jérôme Galon, Anne Costes, Fátima Sánchez‐Cabo et al. · Science · 2006 · 6.5K citations
Medicine, Immunology, Oncology +17
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan et al. · New England Journal of Medicine · 2013 · 4.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Andrea Facciabene, Xiaohui Peng, Ian S. Hagemann et al. · Nature · 2011 · 1.4K citations
Medicine, Cancer Biology, Oncology +14
Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
Helena Harlin, Yuru Meng, Amy Peterson et al. · Cancer Research · 2009 · 1.1K citations · Full text
Medicine, Immunology, Oncology +17